title: [Icteric hepatitis in a patient with non-Hodgkin's lymphoma treated by rituximab-based chemotherapy].
abstract: We report the case of a patient with non-Hodgkin's lymphoma who, during chemotherapy according to the r-CHOP schedule (rituximab-cyclophosphamide-doxorubicin-vincristine and prednisone), showed a hepatic flare with jaundice. Given the patient's state of asymptomatic carrier of HBsAg, we began a treatment of telbivudine (600 mg/die), resulting in a regression of hepatitis flare and negativization of HBV viraemia.
authors.affiliation: Dipartimento di Medicina Pubblica, Clinica e Preventiva, Seconda Università di Napoli, Italy.
authors.forename: Nicola
authors.initials: N
authors.lastname: Coppola
authors.forename: Addolorata
authors.initials: A
authors.lastname: Masiello
authors.forename: Gilda
authors.initials: G
authors.lastname: Tonziello
authors.forename: Margherita
authors.initials: M
authors.lastname: Macera
authors.forename: Valentina
authors.initials: V
authors.lastname: Iodice
authors.forename: Nunzio
authors.initials: N
authors.lastname: Caprio
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pasquale
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003587:Cytomegalovirus / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000150:complications / Q000175:diagnosis; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D006515:Hepatitis B virus / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000150:complications; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009705:Nucleosides / Q000627:therapeutic use; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011744:Pyrimidinones / Q000627:therapeutic use; D000069283:Rituximab; D000077712:Telbivudine; D013936:Thymidine / Q000031:analogs & derivatives; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D014766:Viremia / Q000150:complications; D014775:Virus Activation
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D009705:Nucleosides; D011744:Pyrimidinones; D000077712:Telbivudine; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D013936:Thymidine